ESC Premium Access

Clinical efficacy and safety outcomes of bempedoic acid for LDL-C lowering therapy in patients at high cardiovascular risk: a systematic review and meta-analysis

Congress Session

About the speaker

Doctor Yingfeng Lin

University Hospital Duesseldorf, Duesseldorf (Germany)
0 follower

57 more presentations in this session

Efficacy of propafenone vs. amiodarone in pharmacological cardioversion of recent-onset atrial fibrillation to sinus rhythm: a pooled meta-analysis of 9 randomized controlled trials

Speaker: Doctor J. Borovac (Split, HR)

Thumbnail

The prevalence and safety of direct oral anticoagulants in patients with non-atrial fibrillation associated intra-cardiac thrombus

Speaker: Doctor A. KANWAL (Valhalla, US)

Thumbnail

Efficiency and safety of the modified protocol for cardioversion of atrial fibrillation using the antiarrhythmic drug niferidil. First results of clinical use.

Speaker: Doctor K. Dzaurova (Moscow, RU)

Thumbnail

The effect of glucagon-like peptide-1 receptor agonists on 24-hour ambulatory blood pressure: a meta-analysis

Speaker: Mrs A. Boulmpou (Thessaloniki, GR)

Thumbnail

Risk of death with sodium-glucose co-transporter-2 inhibitors across the hallmark cardiovascular and renal outcome trials: an updated meta-analysis

Speaker: Mrs A. Boulmpou (Thessaloniki, GR)

Thumbnail

Access the full session

Pharmacology and pharmacotherapy e-posters

Speakers: Doctor Y. Lin, Doctor J. Borovac, Doctor A. KANWAL, Doctor K. Dzaurova, Mrs A. Boulmpou...
Thumbnail

About the event

Image

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Related content

ESC Premium Access

PCSK9 inhibition with alirocumab decreases plasma lipoprotein(a) concentration by a dual kinetic mechanism of action

27 August 2021

ESC Premium Access

Treatment of high- and very high-risk patients for the prevention of cardiovascular events in Europe: baseline demographics from the multinational observational SANTORINI study

27 August 2021

ESC Premium Access

Cardiovascular benefits outweigh risks in patients with atrial fibrillation in REDUCE-IT (Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial)

27 August 2021

This platform is supported by

logo Novo Nordisk